Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $281.27 -1.09%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Charles River Laboratories Int'l (NYSE: CRL) reported Q3 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $277.6 million versus the consensus estimate of $280.45 million.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
